Severe Rebound Effects Found in ‘Relevant’ Number of MS Patients After Stopping Fingolimod

                                                                  

Rebound symptoms after stopping fingolimod (Gilenya) treatment affect a “clinically relevant” number of multiple sclerosis (MS) patients, a study by University of California, San Francisco, researchers reported. The study called attention to the need for determining the best method of sequencing or stopping MS treatments, and highlighted the need to identify factors that increase the risk of severe symptoms after fingolimod cessation.

The change or discontinuation of immunoactive drugs is a sensitive matter, balancing safety and protection against relapse, and is of particular concern to women stopping treatment because of pregnancy. The occurrence of rebound symptoms after fingolimod treatment, however, is not well-studied.

Rebound effects are the re-emergence of symptoms held under control by a treatment once the treatment is stopped. The study, published in the journal JAMA Neurology, investigated electronic medical records, along with magnetic resonance images (MRI), from the UCSF Multiple Sclerosis Center for evidence of rebound symptoms after fingolimod cessation. Records from January 2014 to December 2015 were included in the analysis.

Continue Reading on REBOUND after stopping Fingolimod

Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews